Testosterone recovery after stopping ADT – who is at risk for long-term non-recovery? Presented by Pierre Blanchard, MD Gustave Roussy. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/4aVAN1S Advanced Prostate Cancer Consensus Conference

Great to have the opportunity to discuss with my friend Thomas Zilli the current status and future of prostate/mets radiotherapy in #prostatecancer at #APCCC24 .

Thanks Uromigos Tom Powles Brian Rini, MD for the invitation!

• Testosterone recovery after stopping ADT – Who is at risk for long-term non-recovery?- Pierre Blanchard, MD

Advanced Prostate Cancer Consensus Conference silke gillessen OncoAlert Thomas Zilli Daniel Castellano Piet Ost Dra. María Natalia Gandur Quiroga Deborah Mukherji Neeraj Agarwal, MD, FASCO Rana McKay Michael Hofman Declan Murphy Neha Vapiwala

As long as the community, which often is medoncs discussing radiopharm, as ‘dose’ we are doomed to not make progress. Pains me this basic rad physics 101 terminology is not even known. Now nuc med, who 100% knows the difference, is saying ‘dose’ to over simplify, when they know…

And it’s a wrap! It’s been a wonderful and exciting conference. Thanks silke gillessen aurelius omlin and Advanced Prostate Cancer Consensus Conference !

Let’s meet all in 2026 for #APCCC26

And next year for APCCC Diagnostics led by Ken Herrmann and prof. Stefano Fanti

#APCCC24

Great comments by Daniel E Spratt on PSMA therapy
1. Should be treated as radiation treatment and not drug
2. Activity (not dose) should be adapted to tumor burden to ensure proper efficacy
3. Impact of fractionation needs to be studied
#APCCC24

Brilliant lecture by Michael Hofman on differences between PSMA tracers for diagnostics and therapy in #prostatecancer
1. PSMA11, DCFPyL or PSMA7 likely interchangeable
2. For therapy PSMA617 and I&T: likely radio equivalent
#APCCC24

Prof Louise Emmett’s take on special situations for PSMA radioligand therapy for advanced #prostatecancer :
1. Bone marrow dysfunction: if RLT, then full dose (usually diffuse disease) & monitor closely
2. Kidney failure: renal toxicity not an early issue
#APCCC24

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 Pierre Blanchard, MD ‘s excellent talk on serum testosterone suppression after limited ADT and testosterone recovery 👉implications on QOL, & testosterone replacement Rx👇OncoAlert Oncology Brothers UroToday.com PCF Science Courtney Bugler

No consensus about intermittent systemic therapy at #APCCC24 in mHSPC #prostatecancer , even in deep PSA remission or when MDT is used.

Important avenue for prospective trials, such as tombal PEACE6 de-Escalate

In the below PRESTO trial, intermittent ADT allowed after 2 years of systemic therapy, consistent with expert panel voting.

Experts still favor metastasis directed therapy for oligometastatic #prostatecancer although enrollment in clinical trials is encouraged.

Thanks tombal for the shout out to the oligoPresto trial (part of PEACE 6) that is now 460/550 pts accrued.

Outside of de novo high volume metastatic #ProstateCancer situation, #APCCC24 voting results on who could/should get a triplet…

ARPI it is!

The #APCCC24 recommends the use of ARPI to name the now commonly used drugs: Abi, apa, Enzo and daro. Choosing a common name will clarify the discussion.
Small but necessary and useful/needed change.

Doublet vs triplet therapy in mHSPC. Nick James view at #APCCC24 .

Celebrating the 10th anniversary of the PEACE consortium, a European Prostate Cancer Research Group. 10 years, 10 phase III randomized trials… huge impact on patients, led by Prof Karim Fizazi. Congrats! #APCCC24

Pierre Blanchard, MD Piet Ost Very cogent points made that N0M0 on next gen imaging is a completely different population than that of STAMPEDE. This is why #APCCC24 is so important: imaging and treatment practices have evolved, leading to huge gaps in the evidence that we must identify and then fill.

Hormonal therapy in very high risk M0 #prostatecancer pts. Although voting shows a clear trend/consensus, many experts caution against potential over treatment when extrapolating STAMPEDE criteria to current patients. #APCCC24

Jason Eftathiou’s very reasonable conclusion on adjuvant or salvage radiotherapy for #ProstateCancer in high risk patients at #APCCC24 .

Excellent talk by ⁦Daniel E Spratt⁩ at #APCCC24 on genomic and MMAI classifiers in M0 #prostatecancer .

Issues remain about access, dichotomization and added value compared to currently used risk markers (% positive cores, length of Pattern 4, MRI T stage, PSA density…)